Inclusion Criteria:

1. Be 18 to 70 years of age at time of consent

2. Life expectancy of at least 6 months, in the opinion of the investigator

3. Have histologically confirmed breast, non-small cell lung, ovarian, colorectal,
gastric, prostate, pancreatic, or renal cell cancer, or other tumor type as approved
by the study medical monitor

4. Have evidence of persistent, recurrent, or progressive disease after at least one
course of systemic therapy for locally advanced or metastatic disease, including
chemotherapy, targeted therapy, or immunotherapy

5. Clinical stage 3 or 4 disease

6. ECOG 0 or 1

7. Adequate baseline hematological parameters

8. Have renal and hepatic function laboratory test results not to exceed 1.5 X upper
limit of normal (ULN)

9. If female of child bearing potential, have a negative pregnancy test at screening

10. If fertile male or female of child-bearing potential, agree to consistently use a
highly effective method of birth control (including birth control pills, barrier
device, or intrauterine device) from the time of consent through 3 months following
the last dose of study drug.

Exclusion Criteria:

1. Has medical, social, or psychosocial factors that, in the opinion of the
investigator, could impact safety or compliance with study procedures

2. Is pregnant, breastfeeding, or planning a pregnancy

3. Has received treatment with any systemic chemotherapy, radiation, or experimental
agent within 4 weeks of study drug dosing

4. Known to be positive for HIV, hepatitis B, or hepatitis C

5. Administration of any other vaccine ≤ 4 weeks prior to study enrollment